Targeted therapies in the treatment of advanced/metastatic NSCLC

• Published in: European journal of cancer (1990) Vol. 45; no. 14; pp. 2473 - 2487
• Main Authors: Pallis, A.G, Serfass, L, Dziadziuszko, R, van Meerbeeck, J.P, Fennell, D, Lacombe, D, Welch, J, Gridelli, C
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.09.2009; Elsevier
• Subjects: Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - therapeutic use; Benzenesulfonates - therapeutic use; Bevacizumab; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Cetuximab; EGFR; Erlotinib Hydrochloride; Gefitinib; HDAC; Hematology, Oncology and Palliative Medicine; Humans; IGF; Indoles - therapeutic use; Lung Neoplasms - drug therapy; m-TOR; Medical sciences; Niacinamide - analogs & derivatives; NSCLC; Pharmacology. Drug treatments; Phenylurea Compounds; Piperidines - therapeutic use; Proteasome; Pyridines - therapeutic use; Pyrroles - therapeutic use; Quinazolines - therapeutic use; Sorafenib; Sunitinib; Targeted therapies; Treatment Outcome; Tumors; Tyrosine kinase inhibitors; VEGF; Targeted therapies; m-TOR; NSCLC; VEGF; IGF; EGFR; Tyrosine kinase inhibitors; Proteasome; HDAC; Multicatalytic endopeptidase complex; Histone deacetylase; Targeted therapy; Lung cancer; Metastasis; non-small cell lung carcinoma; Epidermal growth factor receptor; Cancerology; Bronchus disease; Advanced stage; Protein-tyrosine kinase; Lung disease; Enzyme; Respiratory disease; Transferases; Malignant tumor; Peptidases; Vascular endothelium growth factor; Treatment; Hydrolases; Inhibitor; Cancer
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2009.06.005

Abstract The treatment of advanced non-small cell lung cancer (NSCLC) has evolved substantially during the last years. Chemotherapy remains the cornerstone of treatment and prolongs survival with a positive impact on quality of life. However, we seem to have reached a plateau of activity in the treatment of NSCLC. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets has improved the outcome in selected patients with advanced NSCLC. Furthermore, the use of erlotinib and gefitinib is an alternative for second line treatment. Advances in our understanding of molecular biology of cancer and mechanisms of tumourigenesis have further enabled the discovery of several potential molecular targets and development of novel ‘targeted therapies’. The purpose of this study is to review current data on the role of targeted therapies in the treatment of advanced NSCLC.